The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 120.40
Bid: 120.00
Ask: 120.40
Change: 0.00 (0.00%)
Spread: 0.40 (0.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 120.40
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Syncona confident after Q1 market volatility

Tue, 16th Aug 2022 10:06

(Sharecast News) - Healthcare investor Syncona reported net assets of £1.33bn at the end of its first quarter on Tuesday, or 197.9p per share, up from £1.31bn and 194.4p per share at the end of March.

The FTSE 250 company said that made for a net asset value return of 1.8% in the three months ended 30 June, driven by the positive impact of foreign exchange across the portfolio and capital pool.

Its life science portfolio was valued at £561.8m, up from £524.9m, with a return of -0.2% in the quarter.

The share prices of Syncona's listed holdings were still being negatively impacted by market volatility, although the board said it remained "confident" in the fundamentals of its companies.

It added that the portfolio remained funded to deliver on upcoming clinical milestones in the 2023 financial year, with £38m deployed in the period and a capital base of £768.7m as at 30 June, down from £784.9m at the end of March.

The company said that capital base provided it with a strategic advantage, as it looked to fund "exciting" new opportunities while supporting its current portfolio.

"We are pleased with the continued progress across the Syncona portfolio during the quarter, with our companies delivering on a number of operational and clinical milestones," said Martin Murphy, chair and chief executive officer at Syncona Investment Management.

"Our strategic capital base remains a key competitive advantage, enabling us to continue to fund our companies through the current market conditions, with £38m of capital deployed in the quarter, and strongly positioning us to take advantage of exciting opportunities to found new Syncona companies."

Murphy said Syncona was founded with a long-term vision and approach to leverage its experience in managing life science companies through all market cycles.

"We are confident that we can navigate the current environment to deliver strong risk-adjusted returns for our shareholders and fulfil our purpose to extend and enhance human life."

At 0940 BST, shares in Syncona were down 0.2% at 199.2p.

Reporting by Josh White at Sharecast.com.

More News
26 Mar 2021 09:20

Syncona invests USD42 million into Gyroscope to have 54% stake

Syncona invests USD42 million into Gyroscope to have 54% stake

Read more
26 Mar 2021 07:59

Syncona invests £31m in Gyroscope

(Sharecast News) - Syncona has invested $42.3m (£31m) in Gyroscope Therapeutics as part of a $148m financing by the retinal gene therapy company.

Read more
25 Mar 2021 12:23

Syncona portfolio firm Achilles Therapeutics prices US share offering

Syncona portfolio firm Achilles Therapeutics prices US share offering

Read more
4 Mar 2021 12:46

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

Read more
2 Mar 2021 13:45

IN BRIEF: Syncona investee Achilles Therapeutics files for US IPO

IN BRIEF: Syncona investee Achilles Therapeutics files for US IPO

Read more
12 Feb 2021 16:24

IN BRIEF: Syncona's Gyroscope Reports Positive Results From GT005 Test

IN BRIEF: Syncona's Gyroscope Reports Positive Results From GT005 Test

Read more
11 Feb 2021 10:05

Syncona Net Asset Value Dips In Third Quarter, Invests More In Quell

Syncona Net Asset Value Dips In Third Quarter, Invests More In Quell

Read more
11 Feb 2021 07:56

Syncona makes decent progress in December quarter

(Sharecast News) - Healthcare investment company Syncona updated the market on its latest quarter on Thursday, reporting clinical, financial and operational progress across its portfolio in the three months ended 31 December.

Read more
10 Feb 2021 09:41

Syncona Investee Autolus Nets USD100 Million From ADS Offer

Syncona Investee Autolus Nets USD100 Million From ADS Offer

Read more
10 Feb 2021 09:31

Syncona upbeat on Autolus US public offering pricing

(Sharecast News) - Healthcare investor Syncona said on Wednesday that its portfolio company Autolus Therapeutics has priced its underwritten public offering in the United States at $7.00 per American depositary share (ADS).

Read more
8 Feb 2021 13:09

Syncona Investee Freeline Modifies Hemophilia Plan After FDA Feedback

Syncona Investee Freeline Modifies Hemophilia Plan After FDA Feedback

Read more
5 Feb 2021 08:20

Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO

Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO

Read more
5 Feb 2021 08:01

Syncona investment Achilles upbeat on safety review of trials

(Sharecast News) - Healthcare investor Syncona said on Friday that its portfolio company Achilles Therapeutics, which is developing precision T-cell therapies to treat solid tumours, had announced that an independent data and safety monitoring committee had completed the first review of the ongoing, first-in-human phase 1 and 2 'CHIRON' and 'THETIS' trials.

Read more
6 Jan 2021 09:30

Syncona Investee Autolus To Focus On Adult Leukemia Programme in 2021

Syncona Investee Autolus To Focus On Adult Leukemia Programme in 2021

Read more
6 Jan 2021 08:36

Syncona upbeat on developments at Autolus

(Sharecast News) - Life science investor Syncona updated the market on its portfolio company Autolus on Wednesday, announcing that it would prioritise the development of the 'AUTO1' programme for adult acute lymphoblastic leukemia (ALL), based on the positive data generated in its phase 1 and 2 studies to date and a high unmet medical need.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.